130 related articles for article (PubMed ID: 17525764)
1. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma.
Yu Z; Li S; Huang YY; Fong Y; Wong RJ
Cancer Gene Ther; 2007 Aug; 14(8):738-47. PubMed ID: 17525764
[TBL] [Abstract][Full Text] [Related]
2. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity.
Yu Z; Adusumilli PS; Eisenberg DP; Darr E; Ghossein RA; Li S; Liu S; Singh B; Shah JP; Fong Y; Wong RJ
Mol Ther; 2007 Jan; 15(1):103-13. PubMed ID: 17164781
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy.
Yu Z; Li S; Huang YY; Lin SF; Fong Y; Wong RJ
Clin Cancer Res; 2008 Mar; 14(6):1897-904. PubMed ID: 18347193
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
5. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy.
Huang YY; Yu Z; Lin SF; Li S; Fong Y; Wong RJ
J Clin Endocrinol Metab; 2007 May; 92(5):1965-70. PubMed ID: 17327376
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
Wong RJ; Chan MK; Yu Z; Ghossein RA; Ngai I; Adusumilli PS; Stiles BM; Shah JP; Singh B; Fong Y
Clin Cancer Res; 2004 Jul; 10(13):4509-16. PubMed ID: 15240543
[TBL] [Abstract][Full Text] [Related]
7. Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma.
Yu Z; Chan MK; O-charoenrat P; Eisenberg DP; Shah JP; Singh B; Fong Y; Wong RJ
Clin Cancer Res; 2005 Jul; 11(13):4889-97. PubMed ID: 16000587
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
9. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
10. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.
Ogawa F; Takaoka H; Iwai S; Aota K; Yura Y
Anticancer Res; 2008; 28(6A):3637-45. PubMed ID: 19189645
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
[TBL] [Abstract][Full Text] [Related]
12. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus.
Krummenacher C; Baribaud F; Ponce de Leon M; Baribaud I; Whitbeck JC; Xu R; Cohen GH; Eisenberg RJ
Virology; 2004 May; 322(2):286-99. PubMed ID: 15110526
[TBL] [Abstract][Full Text] [Related]
13. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
[TBL] [Abstract][Full Text] [Related]
14. Use of chimeric nectin-1(HveC)-related receptors to demonstrate that ability to bind alphaherpesvirus gD is not necessarily sufficient for viral entry.
Geraghty RJ; Fridberg A; Krummenacher C; Cohen GH; Eisenberg RJ; Spear PG
Virology; 2001 Jul; 285(2):366-75. PubMed ID: 11437670
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
17. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus entry receptor nectin-1 is widely expressed in the murine eye.
Valyi-Nagy T; Sheth V; Clement C; Tiwari V; Scanlan P; Kavouras JH; Leach L; Guzman-Hartman G; Dermody TS; Shukla D
Curr Eye Res; 2004; 29(4-5):303-9. PubMed ID: 15590476
[TBL] [Abstract][Full Text] [Related]
19. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
20. Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion.
Gil Z; Rein A; Brader P; Li S; Shah JP; Fong Y; Wong RJ
Clin Cancer Res; 2007 Nov; 13(21):6479-85. PubMed ID: 17975160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
